Policy & Regulation
Aurinia initiates PRESERVE Phase 4 study of LUPKYNIS combination therapy in lupus nephritis
6 July 2026 - Biopharmaceutical company Aurinia Pharmaceuticals (NASDAQ: AUPH) declared on Monday that it has initiated the PRESERVE Phase 4, multicentre study evaluating LUPKYNIS in combination with ...
Anixa Biosciences advances ovarian cancer CAR-T trial to highest dose level
...
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
6 July 2026 - The Development Center for Biotechnology (DCB), a research institute in Taiwan, said on Friday that six Taiwanese biomedical startups held more than 100 one-on-one business meetings with...
Brii Bio reports Phase 2 end-of-treatment data in chronic hepatitis B
6 July 2026 - Chinese biotechnology company Brii Biosciences Limited (Brii Bio) (HK:2137) has announced end-of-treatment (EOT) results from its ongoing Phase 2b ENRICH and ENHANCE studies investigatin...
Nona Biosciences names new chief operating officer
3 July 2026 - Global biotechnology company Nona Biosciences announced on Thursday the appointment of Dr. Peng Wang as its new chief operating officer (COO).Dr. Wang will be based in Suzhou and will re...
SK bioscience to lead Gates Foundation-funded ROTOR project
3 July 2026 - SK bioscience, a South Korea-based vaccine and biotech company, announced on Thursday that it will lead the Research Optimization & Trial Outcome Recommender (ROTOR) project, an AI-p...